Hangzhou Guangliang Biomedical Co., Ltd.

Main study objectives: To compare the relative bioavailability of the test preparation Bangretinib tablets (1 tablet, specification: 16 mg) and the reference preparation Bangretinib tablets (1 tablet, specification: 16 mg) of Hangzhou Bangshun Pharmaceutical Co., Ltd. in healthy adult subjects after a single oral administration under fasting conditions, and to evaluate the bioequivalence of the two preparations. To evaluate the effect of food on the pharmacokinetic characteristics of Bangretinib tablets (1 tablet/time, specification: 16 mg) in healthy subjects. Secondary study objectives: To observe the safety of a single oral administration of Bangretinib tablets (specification: 16 mg) in healthy subjects under fasting/postprandial conditions.

Primary purpose: To evaluate the effectiveness of OB756 tablets in reducing spleen volume in subjects with intermediate- and high-risk myelofibrosis (MF) who are intolerant to ruxolitinib. Secondary purpose: To evaluate the objective effectiveness rate, spleen response, and improvement of MF-related symptoms in subjects with intermediate- and high-risk myelofibrosis (MF) who are intolerant to ruxolitinib; To evaluate the safety of OB756 tablets in the treatment of subjects with intermediate- and high-risk myelofibrosis (MF) who are intolerant to ruxolitinib.

Main purpose: 1. To evaluate the effectiveness of OB756 tablets in reducing spleen volume in subjects with intermediate- and high-risk myelofibrosis (MF). Secondary purpose: 1. To evaluate the objective effectiveness rate, spleen response, and improvement of MF-related symptoms in subjects with intermediate- and high-risk myelofibrosis (MF) treated with OB756 tablets; 2. To evaluate the safety of OB756 tablets in treating subjects with intermediate- and high-risk myelofibrosis (MF).